Comparative assessment of colitis-related adverse events in multiple myeloma patients treated with teclistamab, ciltacabtagene, and idecabtagene: Incidence, outcomes, and risk assessment.

Authors: Majid Jaberi-Douraki, Remya Ampadi Ramachandran, Xuan Xu, Sandra Ann Mazzoni, Jack Khouri, Louis Williams, Jason Neil Valent, Christy Joy Samaras, Yasar Shad, Faiz Anwer, Shahzad Raza

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.e19510

Source: Full article

---

Abstract

e19510